Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
BACKGROUND
treatment of Mycobacterium ulcerans disease, or Buruli ulcer (BU), has shifted from surgery to treatment with streptomycin(STR)+rifampin(RIF) since 2004 based on studies in a mouse model and clinical trials. We tested two entirely oral regimens for BU treatment, rifampin(RIF)+clarithromycin(CLR) and rifapentine(RPT)+clarithromycin(CLR) in the mouse model.


RESULTS
BALB/c mice were infected in the right hind footpad with M. ulcerans strain 1059 and treated daily (5 days/week) for 4 weeks, beginning 11 days after infection. Treatment groups included an untreated control, STR+RIF as a positive control, and test regimens of RIF, RPT, STR and CLR given alone and the RIF+CLR and RPT+CLR combinations. The relative efficacy of the drug treatments was compared on the basis of footpad CFU counts and median time to footpad swelling. Except for CLR, which was bacteriostatic, treatment with all other drugs reduced CFU counts by approximately 2 or 3 log(10). Median time to footpad swelling after infection was 5.5, 16, 17, 23.5 and 36.5 weeks in mice receiving no treatment, CLR alone, RIF+CLR, RIF alone, and STR alone, respectively. At the end of follow-up, 39 weeks after infection, only 48%, 26.4% and 16.3% of mice treated with RPT+CLR, RPT alone and STR+RIF had developed swollen footpads. An in vitro checkerboard assay showed the interaction of CLR and RIF to be indifferent. However, in mice, co-administration with CLR resulted in a roughly 25% decrease in the maximal serum concentration (Cmax) and area under the serum concentration-time curve (AUC) of each rifamycin. Delaying the administration of CLR by one hour restored Cmax and AUC values of RIF to levels obtained with RIF alone.


CONCLUSIONS
these results suggest that an entirely oral daily regimen of RPT+CLR may be at least as effective as the currently recommended combination of injected STR+oral RIF.
Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Deepak
D
Almeida
Paul J
PJ
Converse
Zahoor
Z
Ahmad
Kelly E
KE
Dooley
Eric L
EL
Nuermberger
Jacques H
JH
Grosset
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D054312:Buruli Ulcer / Q000188:drug therapy*; D017291:Clarithromycin / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D019911:Mycobacterium ulcerans / Q000187:drug effects*; D012293:Rifampin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017291:Clarithromycin; D012293:Rifampin; C018421:rifapentine
PLoS Negl Trop Dis. 2008;2(10):e321
18923711
PLoS Negl Trop Dis. 2008 Mar 26;2(3):e205
18365034
Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4
2530933
Antimicrob Agents Chemother. 2000 Sep;44(9):2367-72
10952581
Antimicrob Agents Chemother. 2002 Oct;46(10):3193-6
12234844
J Antimicrob Chemother. 2000 Feb;45(2):231-3
10660507
J Infect Dis. 1993 Jul;168(1):188-90
8257487
Antimicrob Agents Chemother. 2005 Aug;49(8):3182-6
16048922
Int J Lepr Other Mycobact Dis. 1969 Oct-Dec;37(4):389-97
4918202
Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101
16574936
Clin Microbiol Rev. 1988 Apr;1(2):139-56
3069193
Antimicrob Agents Chemother. 2008 Jun;52(6):1912-6
18391038
Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35
17526760
Science. 1999 Feb 5;283(5403):854-7
9933171
Antimicrob Agents Chemother. 1992 Mar;36(3):548-51
1622164
Antimicrob Agents Chemother. 2007 Oct;51(10):3737-9
17664316
Antimicrob Agents Chemother. 1996 Mar;40(3):552-5
8851569
J Antimicrob Chemother. 2003 Jul;52(1):1
12805255
Br J Cancer. 1977 Jan;35(1):1-39
831755
Lancet. 1999 Sep 18;354(9183):1013-8
10501380
Antimicrob Agents Chemother. 1998 Aug;42(8):2070-3
9687409
PLoS Med. 2007 Dec;4(12):e344
18092886
Clin Infect Dis. 1994 Apr;18 Suppl 3:S233-6
8204775
Lancet. 2010 Feb 20;375(9715):664-72
20137805
Antimicrob Agents Chemother. 2006 Jun;50(6):1921-6
16723546
Antimicrob Agents Chemother. 2001 Nov;45(11):3109-12
11600364
Bull World Health Organ. 2005 Oct;83(10):785-91
16283056
Int J Antimicrob Agents. 2003 Dec;22(6):562-6
14659652
Antimicrob Agents Chemother. 2010 Sep;54(9):3878-83
20585115
J Exp Med. 1960 Sep 1;112(3):445-54
19867175
J Antimicrob Chemother. 2005 Sep;56(3):502-6
16006447